セルトラリン
セルトラリンは広く使用されているヒト用抗うつ薬であり、獣医療においては犬や猫の様々な行動関連疾患の管理に適応外使用(オフラベル使用)されています。 **主な臨床応用:** * **犬:** 攻撃行動、全般性不安、および強迫性障害(例:肢端舐性皮膚炎、尾追い行動)。 * **猫:** 尿マーキング(スプレー行動)、情動性または優位性攻撃行動、不安による不適切な排泄、恐怖症、および強迫性障害。 **臨床上のポイント:** > 他のSSRIと同様に、セルトラリンが十分な臨床効果を発揮するまでには長期間(通常4〜8週間)の治療が必要です。この遅れは、神経受容体のダウンレギュレーションに時間を要するためです。ジェネリック医薬品が利用可能であるため比較的安価であり、長期的な行動管理において魅力的な選択肢となります。
作用機序: Sertraline is a highly selective inhibitor of the presynaptic reuptake of **serotonin (5-hydroxytryptamine or 5-HT)** in the central nervous system. * **Mechanism:** Blocks the **serotonin transporter (SERT)** → prevents the reuptake of serotonin into the presynaptic neuron → increases the concentration of serotonin in the synaptic cleft → prolongs stimulation of postsynaptic **5-HT receptors**. * **Receptor Specificity:** Sertraline has minimal to no effect on the reuptake of dopamine or norepinephrine, and lacks significant affinity for adrenergic, cholinergic, or histaminergic receptors, which minimizes the side effects typically seen with tricyclic antidepressants (TCAs). * **Delayed Onset:** The initial increase in synaptic serotonin stimulates presynaptic **5-HT1A autoreceptors**, which temporarily decreases serotonin release. Over several weeks, these autoreceptors down-regulate, allowing for enhanced serotonin release and the onset of full therapeutic effects.
動物種別の用量
- Treatment of compulsive disorders · 0.5 mg/kg PO once daily · PO · q24h
- Urine marking (spraying), aggression, anxiety-including anxiogenic house soiling, phobias, fears · 0.5-1 mg/kg PO q24h (once daily) · PO · q24h
- Treatment of behavioral diagnoses · 1 mg/kg PO q24h (once a day) · PO · q24h · Minimum 4-6 months · Treat for 3-5 weeks minimum to assess effects; treat until 'well' (minimum another 1-2 months), then treat another 1-2 months minimum. Wean off over 3-5 weeks or longer.
- Treatment of fear, affective or dominance aggression · 0.5-1 mg/kg PO once daily · PO · q24h
- Generalized anxiety disorder · 0.5-1.5 mg/kg PO q24h · PO · q24h
- Treatment of compulsive disorder, anxiety · 0.5-1 mg/kg PO q24h (once daily) · PO · q24h
- Behavioral diagnoses · 0.25-1.3 mg/kg PO q24h · PO · q24h
- Increase inhibitory control (e.g., play-related aggressive behaviour) · 0.5-1.5 mg/kg · PO · q24h · Long-term · Suggested use, but there are no good empirical studies published to support this.
- Treatment of compulsive disorders · 2-4 mg/kg PO once daily or divided twice daily · PO · q24h or q12h
- Behavioral diagnoses · 1-2 mg/kg PO q24h (once daily) · PO · q24h · allow 6-8 weeks for initial trial
投与経路
禁忌
- Known hypersensitivity to sertraline or other SSRIs
- Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) such as selegiline or amitraz
- Concurrent use of cisapride
- History of seizures or epilepsy
- Concurrent use of MAOIs (e.g., selegiline)
有害事象
- Anorexia (common in dogs, usually transient)
- Lethargy or sedation
- Gastrointestinal effects (vomiting, diarrhea)
- Anxiety or irritability
- Insomnia or hyperactivity
- Panting (dogs)
- Changes in elimination patterns (cats)
- Paradoxical aggressive behavior in previously non-aggressive animals
- Lethargy
- Decreased appetite
- Vomiting
- Trembling
- Restlessness
- Gastrointestinal disturbance
- Paradoxical increase in anxiety
- Potential increase in aggression
薬物相互作用
- Buspirone · Increased risk for serotonin syndrome
- Cimetidine · May increase sertraline levels
- Cyproheptadine · May decrease or reverse the effects of SSRIs
- Diazepam · Sertraline may decrease diazepam clearance
- Isoniazid · Increased risk for serotonin syndrome
- MAO Inhibitors (e.g., amitraz, selegiline) · High risk for serotonin syndrome; use contraindicated. A 5-week washout period is required after discontinuing sertraline before starting an MAOI, and a 2-week washout if discontinuing an MAOI before starting sertraline.
- Pentazocine · Serotonin syndrome-like adverse effects possible
- Tramadol · SSRIs can inhibit the metabolism of tramadol to active metabolites, decreasing efficacy and increasing the risk of toxicity (serotonin syndrome, seizures)
- Tricyclic Antidepressants (e.g., clomipramine, amitriptyline) · Sertraline may increase TCA blood levels and increase the risk for serotonin syndrome
- Warfarin · Sertraline may increase the risk for bleeding
- Selegiline (MAOIs) · High risk of fatal serotonin syndrome. Do not use sertraline within 2 weeks of an MAOI, and do not use an MAOI within 6 weeks of stopping sertraline. · major
- Anticonvulsants · Sertraline antagonizes the effects of anticonvulsants and lowers the seizure threshold. · major
モニタリング
- Efficacy (resolution or improvement of behavioral signs)
- Adverse effects, particularly changes in appetite and body weight
- Baseline liver function tests (consider re-testing as needed)
- Baseline ECG (consider re-testing as needed)
- Behavioral response (efficacy and paradoxical aggression/anxiety)
- Appetite and body weight
- Signs of serotonin syndrome (tremors, hyperthermia, agitation)
- Seizure activity
過量投与
**Toxicity Profile:** Most exposures in dogs below 20 mg/kg are not considered serious. However, massive overdoses can be life-threatening. **Clinical Signs of Overdose:** * **Mild to Moderate:** Vomiting, diarrhea, hypersalivation (especially in cats), lethargy, tachycardia, somnolence, and vocalization. * **Severe (Serotonin Syndrome):** Muscle tremors, rigidity, agitation, hyperthermia, vocalization, hypertension or hypotension, tachycardia, seizures, coma, and potentially death. **Management:** Handle aggressively with supportive and symptomatic treatment. Contact an animal poison control center (e.g., ASPCA APCC) for specific guidance.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。